Tocilizumab, an IL-6R antibody, could induce the production of tumor immunity-stimulating factors, such as IL-12, IL-1β, and anti-tumor cytokines, such as TNF-α, and IFN-γ. The gene discussed is IFNG; the disease is neoplasm.